LTGO Stock Chart & Stats
$22.48
--
Market closed
$22.48
--
Day’s Range― - ―
52-Week Range$17.22 - $25.93
Previous CloseN/A
VolumeN/A
Average Volume (3M)332.21K
Market Cap
$1.50B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-2.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding66,299,350
10 Day Avg. Volume235,713
30 Day Avg. Volume332,213
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$57.67Price Target Upside156.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Latigo Biotherapeutics, Inc. News
LTGO FAQ
What was Latigo Biotherapeutics, Inc.’s price range in the past 12 months?
Latigo Biotherapeutics, Inc. lowest stock price was $17.22 and its highest was $25.93 in the past 12 months.
What is Latigo Biotherapeutics, Inc.’s market cap?
Latigo Biotherapeutics, Inc.’s market cap is $1.50B.
When is Latigo Biotherapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Latigo Biotherapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Latigo Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Latigo Biotherapeutics, Inc.’s price is currently Undervalued.
Does Latigo Biotherapeutics, Inc. pay dividends?
Latigo Biotherapeutics, Inc. does not currently pay dividends.
What is Latigo Biotherapeutics, Inc.’s EPS estimate?
Latigo Biotherapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Latigo Biotherapeutics, Inc. have?
Latigo Biotherapeutics, Inc. has 66,299,350 shares outstanding.
What happened to Latigo Biotherapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Latigo Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in LTGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Latigo Biotherapeutics, Inc. Stock Smart Score
Company Description
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
LTGO Stock 12 Month Forecast
Average Price Target
$57.67
▲(156.52% Upside)